Senti Biosciences, Inc. (SNTI)
$0.39+$0.02 (+4.53%) Today
Timothy K. Lu - OfficerTimothy K. Lu - OfficerSenti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
No Form 4 activity for SNTI in the last 90 days.
9 Form 4 filings on record, the earliest from Dec 10, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Kanya Rajangam - Officer | Tax withholding / forfeiture | Common Stock | 10,757 | $0.00 | - | |
| Timothy K. Lu - Officer | Tax withholding / forfeiture | Common Stock | 80,666 | $0.00 | - | |
| Kanya Rajangam - Officer | Tax withholding / forfeiture | Common Stock | 1,384 | $0.00 | - | |
| Timothy K. Lu - Officer | Tax withholding / forfeiture | Common Stock | 4,191 | $0.00 | - | |
| Bryan Daniel Baum - Director | Grant or award | Stock Option (Right to Buy) | 43,900 | $0.00 | - | |
| BAYER HEALTHCARE LLC - 10% Owner | Open-market purchase | Series A Convertible Preferred Stock | 2,222 | - | - | |
| BAYER HEALTHCARE LLC - 10% Owner | Open-market purchase | Warrant | 3,333,000 | - | - | |
| Fran Schulz - Director | Grant or award | Stock Option (Right to Buy) | 12,500 | $0.00 | - | |
 Donald F. Tang - Director | Grant or award | Stock Option (Right to Buy) | 12,500 | $0.00 | - | |
| Kanya Rajangam - Officer | Grant or award | Series A Convertible Preferred Stock | 33 | $2,250.00 | $74K | |
| Kanya Rajangam - Officer | Grant or award | Common Stock Warrant (right to buy) | 49,500 | $0.00 | - |
Senti Biosciences, Inc. (SNTI) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-03-11. The full record for SNTI runs to 9 Form 4 filings, the earliest from 2024-12-10. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of SNTI were filed in the last 90 days. 2 purchases are on record for this company.
No insider sales of SNTI were filed in the last 90 days.
This page tracks SNTI Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add SNTI to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
